1. Home
  2. MGX vs EDAP Comparison

MGX vs EDAP Comparison

Compare MGX & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGX
  • EDAP
  • Stock Information
  • Founded
  • MGX 2018
  • EDAP 1979
  • Country
  • MGX United States
  • EDAP France
  • Employees
  • MGX N/A
  • EDAP N/A
  • Industry
  • MGX
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • MGX
  • EDAP Health Care
  • Exchange
  • MGX NYSE
  • EDAP Nasdaq
  • Market Cap
  • MGX 65.0M
  • EDAP 53.8M
  • IPO Year
  • MGX 2024
  • EDAP 1997
  • Fundamental
  • Price
  • MGX $1.53
  • EDAP $2.20
  • Analyst Decision
  • MGX Strong Buy
  • EDAP Buy
  • Analyst Count
  • MGX 4
  • EDAP 3
  • Target Price
  • MGX $14.75
  • EDAP $8.50
  • AVG Volume (30 Days)
  • MGX 354.0K
  • EDAP 77.7K
  • Earning Date
  • MGX 05-16-2025
  • EDAP 05-15-2025
  • Dividend Yield
  • MGX N/A
  • EDAP N/A
  • EPS Growth
  • MGX N/A
  • EDAP N/A
  • EPS
  • MGX N/A
  • EDAP N/A
  • Revenue
  • MGX $52,295,000.00
  • EDAP $66,378,507.00
  • Revenue This Year
  • MGX N/A
  • EDAP $0.74
  • Revenue Next Year
  • MGX $6.95
  • EDAP $0.37
  • P/E Ratio
  • MGX N/A
  • EDAP N/A
  • Revenue Growth
  • MGX 16.84
  • EDAP 6.11
  • 52 Week Low
  • MGX $1.23
  • EDAP $1.26
  • 52 Week High
  • MGX $8.18
  • EDAP $7.36
  • Technical
  • Relative Strength Index (RSI)
  • MGX 49.74
  • EDAP 59.80
  • Support Level
  • MGX $1.40
  • EDAP $2.02
  • Resistance Level
  • MGX $1.64
  • EDAP $2.25
  • Average True Range (ATR)
  • MGX 0.14
  • EDAP 0.18
  • MACD
  • MGX 0.00
  • EDAP 0.06
  • Stochastic Oscillator
  • MGX 48.52
  • EDAP 83.84

About MGX METAGENOMI INC

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: